Pmv Other Assets vs Accounts Payable Analysis

PMVP Stock

USD 1.60 0.01 0.63%

Pmv Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pmv Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pmv Pharmaceuticals is a good investment. Please check the relationship between Pmv Pharmaceuticals Other Assets and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pmv Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Pmv Stock, please use our How to Invest in Pmv Pharmaceuticals guide.

Other Assets vs Accounts Payable

Other Assets vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pmv Pharmaceuticals Other Assets account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Pmv Pharmaceuticals' Other Assets and Accounts Payable is -0.32. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Pmv Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pmv Pharmaceuticals' Other Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Pmv Pharmaceuticals are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Assets i.e., Pmv Pharmaceuticals' Other Assets and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.32

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Other Assets

Accounts Payable

An accounting item on the balance sheet that represents Pmv Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Pmv Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Pmv Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pmv Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pmv Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Pmv Stock, please use our How to Invest in Pmv Pharmaceuticals guide.At this time, Pmv Pharmaceuticals' Tax Provision is relatively stable compared to the past year. As of 11/28/2024, Issuance Of Capital Stock is likely to grow to about 52.1 M, while Selling General Administrative is likely to drop slightly above 17.1 M.

	2021	2022	2023	2024 (projected)
Interest Income	449K	3.6M	9.8M	10.3M
Net Interest Income	449K	3.6M	9.8M	10.3M

Interest Income Net Interest Income

Pmv Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital
Total Assets		0.89	0.85	0.99	0.81	0.98	0.67	-0.7	-0.74	0.75	0.76	0.66	0.44	-0.2	0.99	0.89	0.57	-0.91	0.97	0.96	-0.9	0.99	0.66	1.0	0.9	0.99
Other Current Liab	0.89		0.99	0.9	0.89	0.92	0.9	-0.39	-0.9	0.87	0.42	0.88	0.44	-0.38	0.83	0.89	0.88	-0.88	0.86	0.96	-0.86	0.9	0.87	0.84	0.94	0.82
Total Current Liabilities	0.85	0.99		0.85	0.92	0.88	0.92	-0.29	-0.92	0.92	0.35	0.89	0.46	-0.38	0.8	0.91	0.9	-0.83	0.82	0.94	-0.79	0.85	0.89	0.8	0.93	0.78
Total Stockholder Equity	0.99	0.9	0.85		0.78	1.0	0.69	-0.73	-0.74	0.7	0.74	0.66	0.45	-0.19	0.98	0.85	0.6	-0.95	0.97	0.97	-0.95	1.0	0.67	0.98	0.91	0.98
Other Liab	0.81	0.89	0.92	0.78		0.81	0.77	-0.23	-0.87	0.92	0.41	0.79	0.29	-0.5	0.77	0.96	0.74	-0.69	0.79	0.87	-0.64	0.78	0.78	0.77	0.87	0.76
Net Tangible Assets	0.98	0.92	0.88	1.0	0.81		0.72	-0.71	-0.77	0.71	0.72	0.69	0.41	-0.23	0.97	0.86	0.63	-0.95	0.97	0.98	-0.95	1.0	0.69	0.97	0.91	0.96
Property Plant And Equipment Net	0.67	0.9	0.92	0.69	0.77	0.72		-0.11	-0.9	0.83	0.1	0.85	0.65	-0.25	0.59	0.75	0.97	-0.74	0.71	0.83	-0.71	0.69	0.93	0.6	0.84	0.58
Net Debt	-0.7	-0.39	-0.29	-0.73	-0.23	-0.71	-0.11		0.14	-0.06	-0.9	-0.04	-0.13	-0.17	-0.74	-0.33	0.02	0.67	-0.69	-0.58	0.74	-0.73	-0.04	-0.74	-0.43	-0.75
Retained Earnings	-0.74	-0.9	-0.92	-0.74	-0.87	-0.77	-0.9	0.14		-0.84	-0.16	-0.96	-0.52	0.58	-0.68	-0.87	-0.86	0.8	-0.77	-0.86	0.73	-0.74	-0.98	-0.69	-0.95	-0.67
Accounts Payable	0.75	0.87	0.92	0.7	0.92	0.71	0.83	-0.06	-0.84		0.28	0.81	0.49	-0.32	0.7	0.93	0.81	-0.59	0.7	0.8	-0.53	0.7	0.82	0.7	0.81	0.68
Cash	0.76	0.42	0.35	0.74	0.41	0.72	0.1	-0.9	-0.16	0.28		0.03	0.13	0.2	0.82	0.52	-0.04	-0.56	0.73	0.6	-0.62	0.74	0.03	0.81	0.44	0.82
Non Current Assets Total	0.66	0.88	0.89	0.66	0.79	0.69	0.85	-0.04	-0.96	0.81	0.03		0.41	-0.65	0.59	0.78	0.88	-0.75	0.63	0.78	-0.66	0.66	0.97	0.6	0.89	0.58
Non Currrent Assets Other	0.44	0.44	0.46	0.45	0.29	0.41	0.65	-0.13	-0.52	0.49	0.13	0.41		0.28	0.42	0.46	0.5	-0.48	0.55	0.49	-0.45	0.45	0.61	0.43	0.53	0.42
Other Assets	-0.2	-0.38	-0.38	-0.19	-0.5	-0.23	-0.25	-0.17	0.58	-0.32	0.2	-0.65	0.28		-0.16	-0.38	-0.35	0.31	-0.16	-0.29	0.21	-0.19	-0.5	-0.16	-0.47	-0.15
Cash And Short Term Investments	0.99	0.83	0.8	0.98	0.77	0.97	0.59	-0.74	-0.68	0.7	0.82	0.59	0.42	-0.16		0.87	0.48	-0.88	0.96	0.93	-0.88	0.98	0.59	1.0	0.86	1.0
Common Stock Shares Outstanding	0.89	0.89	0.91	0.85	0.96	0.86	0.75	-0.33	-0.87	0.93	0.52	0.78	0.46	-0.38	0.87		0.68	-0.74	0.87	0.9	-0.69	0.85	0.79	0.87	0.91	0.86
Short Term Investments	0.57	0.88	0.9	0.6	0.74	0.63	0.97	0.02	-0.86	0.81	-0.04	0.88	0.5	-0.35	0.48	0.68		-0.66	0.57	0.75	-0.62	0.6	0.91	0.49	0.77	0.47
Non Current Liabilities Total	-0.91	-0.88	-0.83	-0.95	-0.69	-0.95	-0.74	0.67	0.8	-0.59	-0.56	-0.75	-0.48	0.31	-0.88	-0.74	-0.66		-0.92	-0.94	0.99	-0.95	-0.76	-0.89	-0.93	-0.88
Other Current Assets	0.97	0.86	0.82	0.97	0.79	0.97	0.71	-0.69	-0.77	0.7	0.73	0.63	0.55	-0.16	0.96	0.87	0.57	-0.92		0.96	-0.91	0.97	0.69	0.96	0.91	0.96
Other Stockholder Equity	0.96	0.96	0.94	0.97	0.87	0.98	0.83	-0.58	-0.86	0.8	0.6	0.78	0.49	-0.29	0.93	0.9	0.75	-0.94	0.96		-0.93	0.97	0.8	0.93	0.96	0.92
Total Liab	-0.9	-0.86	-0.79	-0.95	-0.64	-0.95	-0.71	0.74	0.73	-0.53	-0.62	-0.66	-0.45	0.21	-0.88	-0.69	-0.62	0.99	-0.91	-0.93		-0.95	-0.68	-0.88	-0.88	-0.88
Net Invested Capital	0.99	0.9	0.85	1.0	0.78	1.0	0.69	-0.73	-0.74	0.7	0.74	0.66	0.45	-0.19	0.98	0.85	0.6	-0.95	0.97	0.97	-0.95		0.67	0.98	0.91	0.98
Property Plant And Equipment Gross	0.66	0.87	0.89	0.67	0.78	0.69	0.93	-0.04	-0.98	0.82	0.03	0.97	0.61	-0.5	0.59	0.79	0.91	-0.76	0.69	0.8	-0.68	0.67		0.6	0.9	0.58
Total Current Assets	1.0	0.84	0.8	0.98	0.77	0.97	0.6	-0.74	-0.69	0.7	0.81	0.6	0.43	-0.16	1.0	0.87	0.49	-0.89	0.96	0.93	-0.88	0.98	0.6		0.87	1.0
Non Current Liabilities Other	0.9	0.94	0.93	0.91	0.87	0.91	0.84	-0.43	-0.95	0.81	0.44	0.89	0.53	-0.47	0.86	0.91	0.77	-0.93	0.91	0.96	-0.88	0.91	0.9	0.87		0.86
Net Working Capital	0.99	0.82	0.78	0.98	0.76	0.96	0.58	-0.75	-0.67	0.68	0.82	0.58	0.42	-0.15	1.0	0.86	0.47	-0.88	0.96	0.92	-0.88	0.98	0.58	1.0	0.86

Click cells to compare fundamentals

Pmv Pharmaceuticals Account Relationship Matchups

Pmv Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	103.0M	365.5M	331.6M	270.3M	252.2M	254.1M
Other Current Liab	1.7M	4.8M	8.2M	6.8M	9.1M	5.8M
Total Current Liabilities	4.5M	6.4M	12.2M	10.8M	14.0M	9.2M
Total Stockholder Equity	(70.5M)	359.1M	308.6M	246.0M	225.7M	187.5M
Net Tangible Assets	(70.5M)	359.1M	308.6M	246.0M	282.9M	175.4M
Property Plant And Equipment Net	739K	569K	13.2M	20.5M	19.0M	10.1M
Net Debt	95.7M	(361.4M)	(161.3M)	(94.3M)	(24.4M)	(25.6M)
Retained Earnings	(75.4M)	(109.9M)	(167.7M)	(241.0M)	(310.0M)	(294.5M)
Accounts Payable	2.8M	1.6M	3.2M	3.0M	3.2M	2.7M
Cash	73.3M	361.4M	172.5M	108.3M	37.7M	35.8M
Non Current Assets Total	940K	770K	30.3M	23.3M	44.7M	47.0M
Cash And Short Term Investments	101.5M	361.4M	297.2M	241.1M	203.1M	232.1M
Common Stock Shares Outstanding	43.0M	44.8M	45.1M	45.6M	48.0M	47.3M
Short Term Investments	28.2M	0.0	124.7M	132.8M	165.4M	88.5M
Liabilities And Stockholders Equity	103.0M	365.5M	331.6M	270.3M	252.2M	254.1M
Non Current Liabilities Total	169.0M	1.6M	10.8M	13.4M	12.4M	11.8M
Other Current Assets	607K	6.7M	4.1M	6.0M	4.4M	4.0M
Other Stockholder Equity	4.8M	469.0M	476.4M	487.5M	535.5M	362.5M
Total Liab	173.5M	6.4M	23.0M	24.3M	26.5M	48.4M
Net Invested Capital	(70.5M)	359.1M	308.6M	246.0M	225.7M	187.5M
Property Plant And Equipment Gross	739K	569K	13.2M	20.5M	22.3M	23.4M
Total Current Assets	102.1M	364.8M	301.3M	247.0M	207.4M	235.5M
Net Working Capital	97.6M	358.4M	289.1M	236.2M	193.4M	226.3M
Property Plant Equipment	739K	569K	13.2M	11.0M	12.6M	13.2M

Pair Trading with Pmv Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pmv Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pmv Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Pmv Stock

0.66	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.59	PEPG	PepGen	Pair Corr
0.54	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.51	FDMT	4D Molecular Therapeutics	Pair Corr
0.48	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

The ability to find closely correlated positions to Pmv Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pmv Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pmv Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pmv Pharmaceuticals to buy it.

The correlation of Pmv Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pmv Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pmv Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Pmv Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Pmv Stock Analysis

When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC